Description

Eterna Peptides presents premium-grade Libido Drive Capsules (102mg), an advanced oral research formulation engineered to investigate neuroendocrine arousal pathways, localized microvascular perfusion, and behavioral motivation matrices. Combining five high-purity active compounds—PT-141, Oxytocin, N-Acetyl L-Tyrosine, Kisspeptin, and Vasoactive Intestinal Peptide (VIP)—this synergistic multi-pathway matrix serves as an elite investigative tool for tracking concurrent central nervous system ($CNS$) receptor saturation and reproductive endocrine regulation.

### Advanced 102mg Synergistic Compound Profile
Each precisely calibrated capsule contains a standardized mass distribution of targeted research agents:
* **PT-141 / Bremelanotide (3.5mg):** A synthetic cyclic peptide analogue of alpha-MSH. PT-141 is a potent agonist of central melanocortin receptors (primarily MC3R and MC4R) in the hypothalamus. Unlike traditional vascular agents, it bypasses downstream cardiovascular networks to study the direct neural activation of libido, arousal signals, and behavioral desire responses.
* **Oxytocin (3mg):** A naturally modeled nonapeptide heavily investigated within structural neurology as a primary mediator of social bonding, emotional connection, and trust behaviors. It is tracked for its capacity to modulate central dopamine networks, amplifying the reward mechanisms tied to behavioral intimacy.
* **N-Acetyl L-Tyrosine / NALT (90mg):** A highly bioavailable acetylated derivative of the essential amino acid L-tyrosine. NALT functions as a critical metabolic precursor to catecholamine neurotransmitters, supporting the rapid synthesis of dopamine, norepinephrine, and epinephrine to maintain cognitive stamina, mood stability, and alert drive states under mental fatigue modeling.
* **Kisspeptin-10 (5.25mg):** A truncated synthetic peptide fragment derived from the KISS1 gene. Kisspeptin functions as a critical upstream driver of the hypothalamic-pituitary-gonadal (HPG) axis, binding directly to GPR54 (KISS1R) receptors to stimulate pulsatile Gonadotropin-Releasing Hormone (GnRH) and support homeostatic reproductive hormone balances.
* **VIP / Vasoactive Intestinal Peptide (0.25mg / 250mcg):** A naturally occurring 28-amino-acid peptide investigated for its potent smooth muscle relaxant and vasodilatory pathways. VIP induces localized adenylate cyclase activation, increasing cyclic AMP levels to study microvascular blood flow optimization across targeted peripheral tissues.

### Research Applications
In preclinical and in vitro laboratory models, Libido Drive Capsules 102mg are actively utilized to investigate:
* Hypothalamic melanocortin receptor activation (MC3R/MC4R) and central arousal signaling cascades.
* Upstream HPG axis tracking, pulsatile gonadotropin release, and endocrine balance optimization.
* Neurotransmitter synthesis dynamics, dopamine path optimization, and central stress response mitigation.
* Specialized microvascular tissue perfusion, smooth muscle relaxation kinetics, and peripheral vasodilation pathways.
* The baseline bioavailability, chemical stability, and absorption kinetics of oral multi-peptide compound encapsulation.

Our Libido Drive Capsules are manufactured under strict laboratory quality control guidelines to ensure absolute ingredient standardization, high compound purity, and dependable experimental reproducibility.

—
*Disclaimer: This product is sold strictly for laboratory research and development use only. It is not intended for human consumption, diagnostic, or therapeutic purposes.*